Cyrus Mody, MD
Neurology · Los Angeles, CANPI 1629022736
Payments from drug & device makers
Across 315 payments — averaging $29.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- SK Life Science, Inc.$791
- UCB, Inc.$766
- Novartis$612
- MDD US Operations, LLC$548
- Biogen$477
- plus $5K from 32 others
What the payments were for
- Speaking & faculty fees$481%
- Travel & lodging$160%
- Food & beverage$9,34399%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $1,235 |
| SK Life Science, Inc. | 23 | $791 |
| UCB, Inc. | 21 | $766 |
| Novartis | 35 | $612 |
| MDD US Operations, LLC | 21 | $548 |
| Biogen | 16 | $477 |
| Lilly USA, LLC | 17 | $431 |
| Teva Pharmaceuticals USA, Inc. | 9 | $408 |
| AstraZeneca(2 entities) | 11 | $400 |
| Impulse Dynamics (USA) Inc. | 2 | $355 |
| Acadia Pharmaceuticals Inc | 16 | $344 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $342 |
| Sanofi | 14 | $322 |
| Biohaven Pharmaceuticals, Inc. | 14 | $310 |
| Regeneron Healthcare Solutions, Inc. | 2 | $235 |
| EMD Serono, Inc. | 5 | $191 |
| Vifor Pharma, Inc. | 2 | $183 |
| Amgen(2 entities) | 6 | $182 |
| Eisai Inc. | 6 | $169 |
| Kyowa Kirin, Inc. | 8 | $162 |
| Pfizer | 6 | $148 |
| Amarin Pharma, Inc. | 1 | $118 |
| Scpharmaceuticals Inc. | 1 | $118 |
| Genentech USA, Inc. | 3 | $92 |
| Argenx US, Inc. | 2 | $69 |
| Lundbeck LLC | 2 | $58 |
| Abbott | 2 | $49 |
| Acorda Therapeutics, Inc | 2 | $48 |
| Forte Bio-pharma LLC | 1 | $35 |
| Mallinckrodt Enterprises LLC | 1 | $31 |
| Neurelis, Inc. | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $30 |
| Catalyst Pharmaceuticals, Inc. | 1 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Impel Pharmaceuticals Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,420 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NeuproRotigotine | 13 | $17,176 |
| Rasagiline Mesylate | 23 | $7,970 |
| Memantine Hcl | 227 | $7,933 |
| Rivastigmine | 21 | $4,150 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 92 | $2,628 |
| Memantine Hcl ErMemantine Hcl | 22 | $1,567 |
| Donepezil Hcl | 91 | $1,277 |
| Levetiracetam | 34 | $1,176 |
| Primidone | 28 | $920 |
| Gabapentin | 40 | $871 |
| Propranolol Hcl | 56 | $626 |
| Pregabalin | 19 | $554 |
| Amitriptyline Hcl | 33 | $530 |
| Cyclobenzaprine Hcl | 67 | $415 |
| ClopidogrelClopidogrel Bisulfate | 27 | $289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Neupro | $766 | $17,17613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.